<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="77298">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01993745</url>
  </required_header>
  <id_info>
    <org_study_id>200804046R</org_study_id>
    <nct_id>NCT01993745</nct_id>
  </id_info>
  <brief_title>The Analysis of Heart Rate Variability With 24hrs Holter ECG and Serum Cardiac Fibrosis Markers in Critical Illness Patients Who Are With Cardiogenic Shock, With ECMO or IABP Support, or With APACH II Score &gt;25)</brief_title>
  <official_title>The Analysis of Heart Rate Variability With 24hrs Holter ECG and Serum Cardiac Fibrosis Markers in Critical Illness Patients Who Are With Cardiogenic Shock, With ECMO or IABP Support, or With APACH II Score &gt;25)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>National Taiwan University Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>National Taiwan University Hospital</source>
  <oversight_info>
    <authority>Taiwan: Department of Health</authority>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The study is to show the prognostic factor of HRV parameter and cardiac fibrosis markers in
      critical illness patients
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The analysis of Heart Rate Variability with 24hrs Holter ECG and serum cardiac fibrosis
      markers in critical illness patients who are with cardiogenic shock, with ECMO or IABP
      support, or with APACH II score &gt;25)
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>May 2008</start_date>
  <completion_date type="Actual">December 2009</completion_date>
  <primary_completion_date type="Actual">May 2009</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Observational</study_type>
  <study_design>Observational Model: Case Control, Time Perspective: Cross-Sectional</study_design>
  <primary_outcome>
    <measure>Heart Rate Variability and serum cardiac fibrosis markers in critical illness patients</measure>
    <time_frame>2-4weeks</time_frame>
    <safety_issue>No</safety_issue>
    <description>Outcome measurement:
The measure is a composite outcome measure consisting of multiple measures (results to be reported as a single value for each Arm/Group), no changes are required
List the primary condition or disease being studied Shock needing ECMO support</description>
  </primary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Actual">106</enrollment>
  <condition>Cardiogenic Shock,</condition>
  <condition>With ECMO or IABP Support,</condition>
  <condition>With APACH II Score &gt;25)</condition>
  <arm_group>
    <arm_group_label>Study group</arm_group_label>
    <description>ECMO Patients survived</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Control</arm_group_label>
    <description>ECMO Patient died</description>
  </arm_group>
  <eligibility>
    <study_pop>
      <textblock>
        adult age&gt;18 years old
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  critical illness patients who are with cardiogenic shock, with ECMO or IABP support,
             or with APACH II score &gt;25)

        Exclusion Criteria:

          -  pacemaker rhythm, not sign the permit
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>National Taiwan University Hospital</name>
      <address>
        <city>Taipei</city>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Taiwan</country>
  </location_countries>
  <verification_date>November 2013</verification_date>
  <lastchanged_date>November 20, 2013</lastchanged_date>
  <firstreceived_date>October 29, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>ECMO</keyword>
  <keyword>APACH II score</keyword>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Critical Illness</mesh_term>
    <mesh_term>Fibrosis</mesh_term>
    <mesh_term>Shock</mesh_term>
    <mesh_term>Shock, Cardiogenic</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
